Anuja Java

TL;DR: It is proposed that the combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19 and create a basis for clinical trials of complement inhibitors in life-threatening illness.

TL;DR: Insights gained from contemporary genetics are summarized for understanding how dysregulation of this powerful innate immune system leads to these human diseases.

TL;DR: Four rare loss-of-function variants in CFH associated with AMD were identified: missense variant CFH 1:196646753 (C192F) segregated perfectly within a family characterized by advanced AMD and drusen temporal to the macula, and two other missense variants were produced recombinantly.

TL;DR: The results reveal that a CR1 functional deficiency is a mechanism of intraglomerular AP dysregulation and could influence the localization of the glomerular C3 deposits.

TL;DR: Insight is provided into the pathogenesis and novel treatment of de novo TMA, the beneficial effects of complement inhibitors in this disease are highlighted, and it is shown that they can be safely discontinued once the inciting etiology is addressed.